source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.BioPharma Dive · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about an FDA gender rule change, its program for one-day inspections, and moreAn FDA proposal to remove references to “gender” from its regulations sparked concerns about unintended consequences on researchSTAT · 3mo ago↗ source
- 'Pharma, not really’: Top young AI talent shuns careers at big drugmakersRIO DE JANEIRO — Mazdak Abulnaga should be the poster child for the type of employee pharma companies want to hire this year. Abulnaga, a 33-year-old postdoctoral fellow at MIT and Harvard Medical…Endpoints